This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): MabCampath
BioMedTracker has separate drug profiles for alemtuzumab. Please also see Lemtrada for multiple sclerosis.
Alemtuzumab is a humanized monoclonal antibody that binds to CD52, a cell surface receptor found on B and T lymphocytes, a majority of lymphocytes, macrophages, NK cells, and a subpopulation of granulocytes. The proposed mechanism of action is antibody-dependent lysis of the target cells following binding of alemtuzumab to the cell surface CD52 receptor.
Millennium, Ilex and Genzyme
Campath was developed with a 50-50 joint venture between Millennium and Ilex. At the end of 2001, Ilex acquired Millennium's equity interest in the partnership. Millennium receives payments and royalties. On December, 21 2004 Genzyme completed its acquisition of Ilex Oncology, including Campath.
Schering and Genzyme
Schering AG holds exclusive worldwide marketing and distribution rights, plus additional exclusive rights in Japan and the Pacific Rim to Campath (MabCampath in Europe). In the United States, the product is marketed by Berlex Laboratories, a U.S. affiliate of Schering AG. As part of its settlement with the FTC prior to the closing of the transaction, Genzyme has transferred to Schering exclusive responsibility for the development and commercialization of Campath in solid organ transplantation, and Genzyme will no longer receive a share of U.S. profits from the use of the product in this area. The agreement with...See full deal structure in Biomedtracker
Partners: Bayer AG BTG plc Takeda Pharmaceutical Company Ltd
Additional information available to subscribers only: